West Pharmaceutical Services (WST) Revenue (2009 - 2026)

West Pharmaceutical Services has disclosed Revenue across 18 years of filings, most recently posting $844.9 million for Q1 2026.

• Revenue for Q1 2026 came in at $844.9 million, up 21.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 11.23% YoY), and the FY2025 annual result was $3.1 billion, up 6.25% from the prior year.
• Revenue came in at $844.9 million for Q1 2026 at West Pharmaceutical Services, up from $805.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $844.9 million in Q1 2026 to a low of $686.9 million in Q3 2022.
• The 5-year median for Revenue is $746.9 million (2024), against an average of $744.1 million.
• Across the five-year window, Revenue decreased 6.86% in 2024 and increased 21.05% in 2026, its largest moves.
• West Pharmaceutical Services' Revenue stood at $708.7 million in 2022, then climbed by 3.29% to $732.0 million in 2023, then rose by 2.3% to $748.8 million in 2024, then increased by 7.51% to $805.0 million in 2025, then climbed by 4.96% to $844.9 million in 2026.
• The last three Revenue figures came in at $844.9 million (Q1 2026), $805.0 million (Q4 2025), and $804.6 million (Q3 2025), per Business Quant data.